3,000 pancreatic cancer patients enrolled in major drug study
NCT ID NCT06375473
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study is observing 3,000 Chinese patients with pancreatic cancer who are receiving a drug called irinotecan liposome. Researchers are collecting real-world data on side effects, survival, and how well the drug controls the cancer. The goal is to understand the drug's safety and effectiveness outside of controlled clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincial Cancer Hospital
RECRUITINGHefei, Anhui, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Provincial People's Hospital
RECRUITINGHenan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ningbo Medical Center Lihuili Hospital
RECRUITINGNingbo, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking Unicersity First Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Renji，Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Guangxi Medical University
RECRUITINGNanning, Guangxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wuhan Union Hospital of China
RECRUITINGWuhan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.